Causal Effects of Prenatal Drug Exposure on Birth Defects with Missing
  by Terathanasia by Ying, Andrew et al.
Causal Effects of Prenatal Drug Exposure on
Birth Defects with Missing by Terathanasia
Andrew Ying∗
Department of Mathematics, University of California, San Diego
and
Ronghui Xu
Department of Mathematics, Department of Family Medicine and Public
Health, University of California, San Diego
and
Christina D. Chambers
Department of Pediatrics, Department of Family Medicine and Public
Health, University of California, San Diego
and
Kenneth Lyons Jones
Department of Pediatrics, University of California, San Diego
∗The authors gratefully acknowledge Professor Donald Bruce Rubin for stimulating discussions on the
principal effects. AY was partially supported by the Achievement Rewards for College Scientists (ARCS)
Scholarship. AY was awarded the Student Poster Award based on this work at the 2019 Conference on
Lifetime Data Science: Foundations and Frontiers. AY was awarded the 2020 Lifetime Data Science
Section of the American Statistical Association Student Paper Award at the 2020 Joint Statistical Meetings.
1
ar
X
iv
:2
00
4.
08
51
0v
1 
 [s
tat
.A
P]
  1
8 A
pr
 20
20
Abstract
We investigate the causal effects of drug exposure on birth defects, motivated by
a recent cohort study of birth outcomes in pregnancies of women treated with a given
medication, that revealed a higher rate of major structural birth defects in infants
born to exposed versus unexposed women. An outstanding problem in this study
was the missing birth defect outcomes among pregnancy losses resulting from spon-
taneous abortion. This led to missing not at random because, according to the theory
of “terathanasia”, a defected fetus is more likely to be spontaneously aborted. In ad-
dition, the previous analysis stratified on live birth against spontaneous abortion,
which was itself a post-exposure variable and hence did not lead to causal interpreta-
tion of the stratified results. In this paper we aimed to estimate and provide inference
for the causal parameters of scientific interest, including the principal effects, making
use of the missing data mechanism informed by terathanasia. During this process
we also dealt with complications in the data including left truncation, observational
nature, and rare events. We report our findings which shed light on how studies on
causal effects of medication or other exposures during pregnancy may be analyzed.
Keywords: Average treatment effect; Left truncation; Missing not at random; Principal
stratification; Selection model.
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1. Introduction
Our work was motivated by a recent observational study carried out by the North Amer-
ican Organization of Teratology Information Specialists (OTIS), on the use of a specific
medication during pregnancy. Analysis of the data found that the proportion of liveborn
infants with major birth defects was higher for women exposed to the medication com-
pared to unexposed women with the same underlying diseases. The biological mechanism,
if any, that could explain the elevated birth defect rates was not understood, due to the
lack of a pattern of major birth defects as traditionally seen with other teratogens such as
thalidomide.
One possible explanation for the increased rate of birth defects in live born infants could
be related to the concept of “terathanasia”. This refers to the natural screening process
whereby malformed conceptuses are preferentially spontaneously lost in the early weeks of
pregnancy, thereby reducing the birth prevalence of congenital malformations identified in
live born infants. Expanding on this concept, Warkany (1978) further suggested that a
maternal exposure early in pregnancy could influence the process of terathanasia. He cited
an animal study in which prenatal exposure to the medication thyroxine led to differential
mortality of embryos with cleft lip, thus reducing the number of surviving offspring with
cleft lip. It is also possible that maternal exposure to an agent early in pregnancy could
suppress the natural screening process of terathanasia by “rescuing” or preventing spon-
taneous loss of malformed embryos. In this scenario, a lower rate of spontaneous abortion
following exposure to a specific medication might lead to a lower number of malformed em-
bryos lost, and subsequently would result in an increased number of congenital anomalies
in those embryos that survived to live birth.
Table 1 shows pregnancy outcomes for a total 494 pregnant women in the OTIS data
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set for this study: live birth, spontaneous abortion (SAB), therapeutic abortion (TAB),
stillbirth, and lost-to-follow-up (LTFU). SAB was defined as a pregnancy loss occurring
before week 20 of gestation, and stillbirth was defined as a spontaneous pregnancy loss at
20 weeks gestation or later. In the study sample of 494 women, 336 women were exposed to
the medication during the first trimester of their pregnancy, which is the exposure window
of primary interest for major birth defects, and the remaining 158 women were unexposed
to the medication of interest at any time during their pregnancies.
There were a total of 40 observed major birth defects. In addition, there were 27 missing
birth defect outcomes. Twenty-five of these were among pregnancies ending in SAB. In
fact, of the 26 total SAB pregnancy outcomes, only one was observed to have a major birth
defect, while the remaining 25 were missing. As mentioned earlier, SAB is known to be
associated with a higher risk of major birth defects, therefore the fact that most SABs are
missing this outcome falls under the mechanism of missing not at random (MNAR).
Table 1: Missing major birth defects by pregnancy outcomes
Exposed (n = 336) Unexposed (n = 158)
Birth Defect Yes No Missing Yes No Missing
Live Birth 30 287 5 139
SAB 13 1 12
Stillbirth 1
TAB 3 1
LTFU 2
In this paper we apply the established mechanism of terathanasia described earlier to
analyze the causal effect of the medication on major birth defects, while handling the
missing data due to SAB. We adopt the potential outcomes framework to define the causal
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effects, also referred to as the Rubin causal model (Neyman, 1923; Rubin, 1974; Holland,
1986, RCM). It is important to recognize that that the SAB rate was almost twice as high
in the unexposed as in the exposed women. As SAB is itself a post-exposure outcome, it is
possible that medication use early in gestation could have influenced the rate of pregnancy
loss. It has been recognized in the literature (Frangakis and Rubin, 2002) that stratification
based on the observed values of such a variable invalidates any causal interpretation. In
this case, the previous analysis of major birth defects within the liveborn stratum did not
take into account the fact that the pregnancy outcome of live birth versus SAB might be
affected by exposure to the drug. For this purpose we also consider principal stratification
that was proposed to address such post-exposure effects within the potential outcomes
framework (Frangakis and Rubin, 2002).
The rest of the paper proceeds as follows. Due to the multiple pregnancy outcomes
and complexity of the data structure, we devote the next section to describe the multiple
challenges, detailed notation, as well as the general assumptions. Section 3 presents the
approach we use to estimate the average treatment effect on major birth defect. Throughout
the paper we will use the words ‘exposure’ and ‘treatment’ inter-exchangeably. Section 4
presents the principal strata as defined by the potential pregnancy outcomes, the causal
estimands that we are interested in, together with the estimation and inference approach.
Section 5 provides the detailed data analysis using the approaches developed in this paper.
Section 6 contains further discussion.
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2. Challenges, Notation and Assumptions
2.1. Main challenges
In the following we provide a roadmap of the main challenges in analyzing the birth defects
data for causal inference, and outline our solutions to them.
Missing not at random
As shown in Table 1, the major birth defect outcome is missing for most SAB cases.
Meanwhile it is well-established that in the general population SAB cases are at higher risk
of having major birth defects than pregnancies that end in live births (Warkany, 1978).
This results in missing not at random (Little and Rubin, 2019, MNAR). Fortunately, the
terathanasia theory informs us how to model such a missing data mechanism, i.e. using the
so-called ‘selection model’, which models the marginal distribution of the complete data
and the conditional distribution of missingness given the complete data. Here the complete
data corresponds to assuming that all major birth defect outcomes are observed, and the
missing data mechanism can be modeled as the conditional distribution of SAB/stillbirth
given the major birth defect outcomes.
Left Truncation and Right Censoring
Our SAB data is subject to left truncation, because women typically enroll in OTIS preg-
nancy studies after clinical recognition of their pregnancies (Xu and Chambers, 2011). This
leads to selection bias as women who have early SAB events tend not to be captured in
our data. In addition, enrolled pregnancies that are subsequently lost-to-follow-up, for ex-
ample, leads to right censoring. Finally, unlike death, SAB or stillbirth does not happen
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to all pregnancies; when a pregnancy ends in live birth, we may consider it censored for
SAB/stillbirth at that time (i.e. at 20 weeks’ gestation for SAB and at gestational age at
delivery for stillbirth). An alternative consideration is that the pregnancy is ‘cured’ from
SAB/stillbirth if it ends in live birth; we will further discuss this later.
Survival analysis methods have been well studied for left truncated and right-censored
(LTRC) time-to-event data. In particular for length-biased data Qin et al. (2011) further
developed an early framework of Vardi (1989), by augmenting “ghost copies” for each
observed individual in the data set, i.e. through recovery of those similar individuals who
have been left truncated out of the observed data set. These approaches lead to an EM
algorithm, which was further adopted in Hou et al. (2018) for data with an observed cured
portion and applied to SAB data analysis. The “ghost copies” approach will also be used in
this paper, as it integrates nicely with the missing data above so that EM type algorithms
may be applied.
Observational nature and moderate sample size
The prospective cohort studies in pregnancy carried out by OTIS are observational in na-
ture. As such, the presence of confounders is inevitably an important issue to address.
Many approaches exist in the literature; for pregnancy studies with birth defect outcomes
in particular, various ways to select confounders and use propensity scores were discussed
in Xu et al. (2019). Given the numbers of events in Table 1, we will consider parsimo-
nious modeling approaches in the next sections, together with inverse probability weighting
(IPW) using propensity scores (Rosenbaum and Rubin, 1983; D’Agostino Jr, 1998). This
results in the minimal number of parameters that need to be estimated.
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Principal effects and rare events
As mentioned earlier, the original analysis was done on the subset of live born infants.
However, live birth is a post-exposure outcome. For this data set in particular, it is possible
that exposure to the drug has an effect on live birth versus otherwise, as proportionally
fewer SAB’s are seen in the exposed group (Table 1). Principal stratification is a useful
framework for addressing such post-exposure complications (Frangakis and Rubin, 2002).
The principal effects (PE) are causal effects within the principal strata, formed by the
potential outcomes of the post-exposure stratification variable. This, however, does give
rise to more parameters to be estimated, as compared to a single average treatment effect
(ATE) over the whole population. In addition, there are parameters related to the latent
membership of the principal strata. Given the already limited sample size for estimating
the ATE, how to fit the PE models poses perhaps the largest challenge in this paper.
2.2. Outcomes and notation
Among the five types of pregnancy outcomes listed in Table 1, we combine SAB/stillbirth
into one outcome for the purposes of this paper. As mentioned earlier, left truncation exists
in our data for this variable, therefore time to SAB/Stillbirth event will be considered and
survival analysis methods will be applied in order to properly handle this selection bias
(Xu and Chambers, 2011; Hou et al., 2018). In addition, TAB in pregnancy studies should
be considered as a competing risk of SAB (Meister and Schaefer, 2008), but due to the
extremely low number of events in our data, it will be treated as (non-informatively)
right-censored. LTFU is the usual right censoring. Finally, live birth informs us that the
pregnancy is no longer at risk of SAB/stillbirth, and it will be treated as right-censored
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at gestational age at delivery. For all of these survival random variables, the time scale is
gestational age in weeks, and time zero is the start of gestation which is defined as the first
day of the last menstrual period of a pregnant woman.
The data for subjects i = 1, ..., n are treated as independent and identically distributed.
Define
• Di = 1 if subject i is treated or exposed, 0 otherwise;
• Yi = 1 if subject i has a major birth defect, 0 otherwise; note that some Yi’s are
missing;
• Oi = 1 if Yi is observed, 0 otherwise;
• Qi gestational age at study enrollment, i.e. left truncation time;
• Ti time to SAB/stillbirth;
• Ci right censoring time, which can be TAB, LTFU or live birth delivery;
• Xi = min(Ti, Ci);
• ∆i = I(Ti ≤ Ci);
• Mi = 1 if subject i has an event of of SAB/Stillbirth, 0 otherwise; note that Mi is
missing if subject i is right censored;
• Vi the vector of covariates;
• t1 < t2 < · · · < tK the K distinct observed SAB/Stillbirth event times.
In addition, we define the following potential outcomes:
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• (Yi(1), Yi(0)): potential major birth defect outcome under exposure or not, respec-
tively;
• (Mi(1),Mi(0)): potential SAB/stillbirth outcome under exposure or not, respectively;
• (Ti(1), Ti(0)): potential time to SAB/stillbirth under exposure or not, respectively.
2.3. Causal framework and assumptions
The causal relationship of the variables defined above can be depicted in a graphical display
as in Figure 1.
Figure 1: A causal directed acyclic graph (DAG). The dashed lines between D and Y , and
D and (M,T ) are the causal relations in question. The arrow from Y to (M,T ) represents
the effect of “terathanisia”.
D Y M,T
V
We assume the following throughout the paper. The first four assumptions are com-
monly used in causal inference.
Assumption 1 (Stable unit treatment value assumption). The potential outcomes for one
subject are unaffected by the treatment assignments of other subjects, and for each subject
there are no hidden versions of treatment or control being considered.
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Assumption 2 (Consistency). We observe one of the potential outcomes at a time, that is,
Y = D ·Y (1)+(1−D)Y (0), M = D ·M(1)+(1−D)M(0) and T = D ·T (1)+(1−D)T (0).
Assumption 3 (Conditional ignorability). The treatment assignment is randomized, once
given the covariates; that is,
(Y (d),M(d), T (d)) ⊥ D | V, (1)
where ‘⊥’ denotes statistical independence.
Assumption 4 (Positivity). The propensity scores are bounded away from 0 or 1 given
any covariates; that is, there exists ε > 0 such that
ε ≤ P(D = 1|V = v) ≤ 1− ε, for any v. (2)
The next two assumptions are commonly used for survival data, commonly known as
non-informative censoring and truncation; see for example Qin et al. (2011); Hou et al.
(2018). Note that in the selection model to be specified in the next section, the birth defect
outcome Y is a predictor of the SAB outcome T .
Assumption 5 (Conditional independent censoring). C is independent of (T,Q) given
(Y,D, V ), and there exists a finite number τ > 0 such that P(C > τ) = 0 and P(T > τ) > 0.
Assumption 6 (Conditional quasi-independent truncation). The truncation time Q and
the event time T are independent given (Y,D, V ) on the nontruncated region, and there
exists ξ ∈ (0, τ) such that P(Q > ξ) = 0.
Finally, the following assumption is needed for the selection model. It states that once
the information on SAB is included in the data, the major birth defect outcome is missing
at random.
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Assumption 7 (Missing at random given SAB).
P(O = 1|D, Y, V, T,M) = P(O = 1|T,M). (3)
3. Average Treatment Effect
3.1. Models and weighted likelihood
In this section we focus on the average treatment effect (ATE) of the drug exposure on
major birth defects. We consider the following models for the potential outcomes:
P(Y (d) = 1) =
exp(α0 + αD · d)
1 + exp(α0 + αD · d) , (4)
and
P(T (d) > t|Y (d) = y) = exp{−Λ(t) exp(βD · d+ βY · y)}, (5)
where Λ(t) is the cumulative baseline hazard function for the conditional distribution of
T (d) given Y (d). Then exp(αD) is the ATE, which is the causal odds ratio
P (Y (1) = 1)/P (Y (1) = 0)
P (Y (0) = 1)/P (Y (0) = 0)
. (6)
The parameters βD and βY represent the effect of the treatment and birth defect on
SAB/Stillbirth. In particular, βY plays the role of quantifying “terathanasia”; higher βY
implies a stronger effect of terathanasia.
Remark 1. Note that model (4) is in fact saturated. While we might attempt to include the
interaction term between d and y in model (5), it turns out that the estimation algorithm
failed to converge due to too few (7) observed birth defects (Y = 1) in the control group
(D = 0), as seen from Table 1.
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The counterfactual outcome, by definition, is not observed. In order to estimate the
parameters in models (4) and (5), we use the inverse probability (IP) weights to create a
pseudo-randomized sample. This enables us to write down a weighted likelihood based on
the observed variables in order to estimate the parameters in the two structural models (4)
and (5) (Breslow and Wellner, 2007). Specifically, define the stabilized IP weights as
wIPi =
Pˆ(Di = 1)Di
Pˆ(Di = 1|Vi)
+
Pˆ(Di = 0)(1−Di)
Pˆ(Di = 0|Vi)
, (7)
where Pˆ(Di = d|Vi) is an estimated propensity score, and Pˆ(Di = d) is the estimated
probability of exposure or not.
Before we write down the weighted likelihood, we introduce additional notation for the
“ghost copies” of subject i in order to properly account from left truncation. The idea
of “ghost copies” is that for an observed subject i, there are Ai “ghost copies” with the
same value of (Yi, Di, Vi) that have been truncated out and not observed in the data. It
can be seen that Ai follows a geometric distribution with probability of success equal to
P(Ti > Qi|Yi, Di, Qi). Under the nonparametric likelihood framework for semiparametric
models, the “ghost copy” event times Tij < Qi (j = 1, ..., Ai) are discrete random variables
taking values among t1, · · · , tK with probabilities P(Tij = tk|Tij < Qi, Qi). The fact that
the Tij’s are assumed to be discrete is closely related the fact that in a nonparametric
likelihood, the baseline hazard is understood as discretized to point masses λ1, ..., λK at
the observed event times t1, ..., tK (Johansen, 1993; Murphy, 1994, 1995). See Hou et al.
(2018) for more details and discussion on this.
Write α = (α0, αD)
>, β = (βD, βY )>, and θ = (α>, β>, λ1, ..., λK)>. The weighted
likelihood based on the complete data, including the augmented Yi’s if they are missing,
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can then be written:
Lcw(θ) =
n∏
i=1
[
piYii (1− pii)1−Yiλi(Xi)∆iSi(Xi)
Ai∏
j=1
{
λi(Tij)Si(Tij)
}]wIPi
, (8)
where pii = expit(α0 + αDDi), λi(t) = λ0(t) exp(βDDi + βY Yi) with λ0(·) equal to the
corresponding λk, and Si(t) = exp{−Λ(t) exp(βDDi + βY Yi)} with Λ(·) equal to the corre-
sponding cumulative sum of the λk’s. This yields a weighted complete data log-likelihood:
lcw(θ) = logL
c
w(θ)
=
n∑
i=1
wIPi
[
Yi log pii + (1− Yi) log(1− pii) + ∆i log λi(Xi) + logSi(Xi)
+
Ai∑
j=1
{
log λi(Tij) + logSi(Tij)
}]
. (9)
3.2. ES algorithm
To estimate the parameters θ in the weighted complete data log-likelihood (9), we use
an Expectation-Substitution (ES) algorithm, which is very similar to the well-known EM
algorithm but for estimating equations instead of likelihood functions (Rosen et al., 2000;
Elashoff and Ryan, 2004). Note that the weighted likelihood approach is in fact an Z-
estimation approach, leading to sandwich type variance estimates instead of inverse of the
Fisher information. Both EM and ES algorithms have since been applied to nonparametric
(weighted) likelihoods under semiparametric models (Peng and Dear, 2000; Vaida and Xu,
2000; Faig, 2013, for example). In the following we described the ES algorithm as applied
to (9).
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Initialization
We first compute the weights wIPi for 1 ≤ i ≤ n. Pˆ(Di = d|Vi) in the denominators of (7)
can be obtained using any propensity score approaches, for example the R package “twang”
(Ridgeway et al., 2017), for d = 0, 1. In the numerators Pˆ(Di = d) is estimated using the
empirical proportions of each treatment group observed in the data. We then obtain the
initial value θ(0) by treating all the missing Y values as 0, ignoring left truncation, and
fitting a logistic and a Cox regression model corresponding to (4) and (5), respectively,
with weights wIPi . The fitting can be easily done using, for example, ‘glm()’ and ‘coxph()’
functions in R.
E-step
At step t+1, for t = 0, 1, ..., let Q(θ|θ(t)) = Eθ(t) [lcw(θ)|O], where O denotes all the observed
variables. We have
Q(θ|θ(t)) =
n∑
i=1
[
wpi1,i log pii + w
pi
0,i log(1− pii)
+
K∑
k=1
wfi,k,1 log fi(tk|Yi = 1) +
K∑
k=1
wfi,k,0 log fi(tk|Yi = 0)
+wSi,1 logSi(Xi|Yi = 1) + wSi,0 logSi(Xi|Yi = 0)
]
, (10)
where
wpi1,i = w
IP
i {OiYi + (1−Oi)P(t)i (Y misi = 1)}, (11)
wpi0,i = w
IP
i {Oi(1− Yi) + (1−Oi)P(t)i (Y misi = 0)}, (12)
wfi,k,1 = w
IP
i (OiYi + (1−Oi)P(t)i (Y misi = 1))
·[∆i1(Xi = tk) + E(t)i (Ai|Yi = 1)P(t)i (Ti1 = tk|Yi = 1)], (13)
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wfi,k,0 = w
IP
i (Oi(1− Yi) + (1−Oi)P(t)i (Y misi = 0))
·[∆i1(Xi = tk) + E(t)i (Ai|Yi = 0)P(t)i (Ti1 = tk|Yi = 0)], (14)
wSi,1 = w
IP
i (1−∆i)[OiYi + (1−Oi)P(t)i (Y misi = 1)], (15)
wSi,0 = w
IP
i (1−∆i)[Oi(1− Yi) + (1−Oi)P(t)i (Y misi = 0)]. (16)
The expressions for P(t)i (Y misi = y), E
(t)
i (Ai|Yi = y) and P(t)i (Ti1 = tk|Yi = y) in the above
are given in the Supplemental Materials.
S-step
In the S-step we update θ by the maximizer of Q(θ|θ(t)). It can be seen that Q(θ|θ(t)) is
the sum of the following two parts:
Q(θ|θ(t)) = lglm(α) + lcox(β, λ1, · · · , λK), (17)
where
lglm(α) =
n∑
i=1
[
wpi1,i log pii + w
pi
0,i log(1− pii)
]
, (18)
and
lcox(β, λ1, · · · , λK) =
n∑
i=1
{ K∑
k=1
[
wfi,k,1 log fi(tk|Yi = 1) +
K∑
k=1
wfi,k,0 log fi(tk|Yi = 0)
]
+wSi,1 logSi(Xi|Yi = 1) + wSi,0 logSi(Xi|Yi = 0)
}
. (19)
Consequently, we may fit two weighted regression models, using the weights in (18) and
(19) that are computed in (11) - (16) of the E-step above.
The E-step and the S-step are iterated until convergence, which may be declared when
the change in the consecutive parameter values is below a pre-specified threshold; in this
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paper we use L2 norm < 0.00001. Following convergence a sample-based variance estimator
can be obtained, and the details are given in the Supplemental Materials. The asymptotic
properties of the estimator was studied in Ying (2020), which showed that the estimator is
consistent and asymptotically Gaussian.
4. Principal Effects
As mentioned earlier SAB/stillbirth is a post exposure variable, therefore as we defined
before it can take on two potential values Mi(0) and Mi(1) for subject i. As explained in
Frangakis and Rubin (2002) a stratified comparison of the Yi’s based on the observed values
of the Mi’s, is equivalent to comparing P(Yi(1) = 1|Mi(1) = m) versus P(Yi(0) = 1|Mi(0) =
m). Such a comparison is problematic because the set of subjects {i : Mi(1) = m} is not
the same set of subjects {i : Mi(0) = m}, as long as the exposure has non-zero effect
on SAB/stillbirth. Unfortunately this is likely the case here, leading to so-called post-
treatment selection bias in the estimated exposure effect (Rosenbaum, 1984; Robins and
Greenland, 1992; Frangakis and Rubin, 2002).
In this section we consider principal stratification which is the stratification with respect
to the joint potential values of M , and use (M(0),M(1)) to stratify the whole population.
The whole population is then divided into:
1. Always-survivors (SS), (M(0),M(1)) = (0, 0), are those subjects who will not expe-
rience SAB/stillbirth no matter whether treated or not;
2. Treatment-survivors (NS), (M(0),M(1)) = (1, 0), are those subjects who will expe-
rience SAB/stillbirth only when not treated;
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3. Control-survivors (SN), (M(0),M(1)) = (0, 1), are those subjects who will experience
SAB/stillbirth only when treated;
4. Never-survivors (NN), (M(0),M(1)) = (1, 1), are those subjects who will experience
SAB/stillbirth no matter treated or not.
Table 2 shows the division of the whole population into the above four principal strata.
Table 2: Division of the whole population into four principal strata
M(1)
0 1
M(0)
0 Always-survivors (SS) Control-survivors (SN)
1 Treatment-survivors (NS) Never-survivors (NN)
Due to the very limited number of events in our data, in the following we further make a
monotonicity assumption that eliminates the ‘control-survivor’ stratum, in order to reduce
the number of parameters that need to be estimated later. This is the supported by the
fact that the estimated βD under model (5) is negative (see Section 5); that is, the drug
reduces the risk of SAB/stillbirth. We assume
Assumption 8 (Monotonicity). M(1) ≤M(0) with probability one.
It is unknown which principal stratum a subject belongs to. However, certain rela-
tionship can be derived between the latent principal strata and the observed group of
subjects defined according to (D,M obs), where M obs = M if observed, and M obs = ?
otherwise. Table 3 summarizes the correspondence between the observed groups and the
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latent strata. For example, those with (Di,M
obs
i ) = (0, 0) i.e. no SAB/stillbirth events
under no treatment, can only belong to the always-survivor stratum SS due to the mono-
tonicity assumption. On the other had, those with (Di,M
obs
i ) = (0, 1) i.e. having had
SAB/stillbirth events under no treatment, can belong to either NS (treatment-survivors)
or NN (never-survivors). Missing Mi leads to possibilities of all three strata, etc. Table
3 also gives the number of subjects (group size) and the number of birth defects in each
observed group for the OTIS data.
Table 3: Correspondence between the observed O(D,M obs) groups and the latent principal
strata
O(D,M obs) Size Birth Defects Missing Defects Principal Strata
O(0, 0) 144 5 0 SS
O(0, 1) 13 1 12 NS, NN
O(0, ?) 1 1 0 SS, NS, NN
O(1, 0) 317 30 0 SS, NS
O(1, 1) 14 0 13 NN
O(1, ?) 5 3 2 SS, NS, NN
Following Frumento et al. (2012) we define G as the latent indicator for the principal
strata, which takes values in {SS,NS,NN}. We assume a multinomial distribution for the
principal strata membership:
P(G = g) =
exp(γg)∑
g′ exp(γg′)
, (20)
where g ∈ {SS,NS,NN}, and we treat the group SS as reference, i.e. γSS = 0. Parallel to
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model (4) for the ATE in Section 3, the causal estimands are now the principal effects αD,g
in each stratum:
P(Y (d) = 1|G = g) = exp(α0,g + αD,g · d)
1 + exp(α0,g + αD,g · d) . (21)
The parameters of scientific interest in models like the above can vary depending on
the applications. In a somewhat similar-in-appearance but different setting referred to as
‘truncation by death’, it is often argued that the only stratum to be considered is equivalent
to our ‘always-survivors’, and the principal effect there is referred to as the ‘survivor average
causal effect’ (SACE) (Ding et al., 2011; Yang and Small, 2016; Ding et al., 2018). We
further discuss the difference in our setup in the last section of the paper. In the context
of drug exposure during pregnancy, we can be potentially interested in the principal effects
in all strata. This is at least partially due to the scientific need to understand the drug
mechanism in causing birth defects (or not) in both live born infants as well as in fetuses
that are lost due to SAB/stillbirth. Furthermore, it can be helpful for some women with
a pregnancy loss to know that the fetus was malformed. It will be seen, however, due to
the limited number of events in our data, we may not be able estimate all the parameters
in (21), and we will have to offset some of them as sensitivity parameters. We defer this
discussion to the data analysis section.
Finally in order to handle left truncation in the data, as before we consider the potential
time to SAB/Stillbirth T (d), but now in each of the three principal strata. We note that
T (d) =∞ in SS, and also in NS if d = 1. On the other hand, T (d) <∞ in NN, and in NS
if d = 0. For these latter three cases where T (d) <∞ we assume:
P(T (d) > t|Y (d) = y,G = g)
= exp [−Λ(t) exp{β0,NS · (1− d) · 1(g = NS) + βD,NN · d · 1(g = NN) + βY · y}] .(22)
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Note that the intercept β0,NN is absorbed in the baseline cumulative hazards Λ(t), and thus
we only have β0,NS and βD,NN in the model above.
We note that the survival model (22) only concerns the timing of the events among
those who are susceptible. This is very similar to the ‘cure’ model concept (Farewell, 1982,
1986; Kuk and Chen, 1992; Sy and Taylor, 2000; Lu and Ying, 2004; Hou et al., 2018).
The effect of drug exposure on the occurrence of SAB/stillbirth, on the other hand, is now
reflected in the sizes of the principal strata. In particular, we may estimate the causal log
odds ratio (Frumento et al., 2012)
log(ORM) = log
{
P(M(1) = 1)/P(M(1) = 0)
P(M(0) = 1)/P(M(0) = 0)
}
(23)
by taking logarithm of
ÔRM =
Pˆ(M(1) = 1)/Pˆ(M(1) = 0)
Pˆ(M(0) = 1)/Pˆ(M(0) = 0)
=
Pˆ(G = NN)
/
[Pˆ(G = NS) + Pˆ(G = SS)]
[Pˆ(G = NN) + Pˆ(G = NS)]
/
Pˆ(G = SS)
=
exp(γˆNN)
{exp(γˆNS) + exp(γˆNN)}{1 + exp(γˆNS)} . (24)
Note that the second line above made use of the monotonicity assumption that P(M(1) =
1,M(0) = 0) = 0. Following the inference results below we may apply the delta method to
obtain a variance estimate of (24).
We provide the likelihood expressions and details of the ES steps as well as inference in
the Supplemental Materials; the expressions are more complex than in the previous section
on ATE.
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Table 4: Distribution of the identified confounders in OTIS study: mean (SD) or n (%).
Confounders Exposed (n = 336) Unexposed (n = 158)
Asthma 45 (13.4%) 32 (20.3%)
Maternal Height (cm) 165 (6.98) 167 (7.01)
Referral Source:∗
Type I 26 (7.7%) 65 (41.1%)
Type II 199 (59.2%) 52 (32.9%)
Type III 111 (33.1%) 41 (26.0%)
∗I: TIS; II: Pharmaceutical Company/Sponsor, Healthcare Professional; III: Patient Support Group, In-
ternet, or Other.
5. Birth Defect Data Analysis
Here we consider the confounders identified in the original analysis which included asthma
(yes/no), maternal height and referral source. A key step in identifying the confounders
was to examine whether or not the relationship between the exposure and the outcome
was altered by including or excluding the covariate in question; more investigation on
confounder selection for birth defect studies was carried out in Xu et al. (2018). The
distribution of the confounders are summarized in Table 4. We use the R package “twang”
(Ridgeway et al., 2017) to estimate the propensity scores Pˆ(Di = 1|Vi) with the above
identified confounders, which are then used to form the stabilized weights as in (7). In
Supplemental Materials we show that all the confounders are well balanced after weighting.
Figure 2 shows the distribution of the left truncation timeQ, as well as the Kaplan-Meier
(KM) estimate of the time to SAB/stillbirth distribution accounting for left truncation.
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Figure 2: Distribution of gestational age at study enrollment (left) and KM estimate for
time to SAB/stillbirth (right)
5.1. Average treatment effect
The purpose of the first part of the analysis is to investigate the robustness of the original
analysis results with respect to the handling of missing major birth defect outcomes. The
estimates of the parameters in (4) and (5) and their standard errors (SE) etc. are presented
in Table 5. From the table we see that the estimated βY > 0 is consistent with the known
“terathanasia” theory mentioned before. However, it has a very wide 95% confidence
interval (CI), which is perhaps not surprising as we only had two observed major birth
defect outcome Yi’s among the 27 SAB/stillbirth events. The results otherwise show that
the drug has a significant effect in increasing major birth defects, with a causal odds ratio
close to 3 which is consistent with the original analysis. In addition, exposure to the drug
has a negative albeit not significant effect on SAB/Stillbirth, reducing the hazard to less
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Table 5: Parameter estimates from the OTIS data for ATE analysis
Estimate (SE) exp(Estimate) 95% CI of OR/HR p-value
α0 -3.336 (0.443) 0.035 (0.014, 0.084) <0.001
αD 1.093 (0.489) 2.983 (1.144, 7.779) 0.025
βD -0.801 (0.498) 0.448 (0.169, 1.191) 0.107
βY 0.485 (1.935) 1.624 (0.036, 72.067) 0.802
than half of the unexposed.
Due to the little confidence we have in the estimated βY as reflected in its wide CI, we
further conduct a sensitivity analysis to examine the robustness of our conclusion about
the ATE αD with respect to the value of βY , which affects the probability of major birth
defects among those with missing values. Following the theory of terathanasia, we restrict
βY to be non-negative, and vary it on the interval [0, 5]; note that 5 would be considered
an extremely large log hazard ratio. Figure 3 shows the posterior probabilities of major
birth defect among the 27 subjects (ordered by their SAB event times) with missing values,
which increase as βY becomes larger. We also note that the probabilities of birth defect
are generally higher for the subjects from the exposed group than the unexposed group.
Figure 4 shows the sensitivity analysis results. Note that as βY increases past 1.4,
αD becomes non-significantly different from zero at 0.05 level two-sided. This makes sense
because as more missing major birth defect outcomes become ‘yes’, the rates of major birth
defect between the exposed and unexposed groups become less differentiated. Meanwhile
βD becomes significantly less than zero, implying that exposure to the drug reduces the risk
of spontaneous abortion. Such a mechanism allows more malformed fetus in the exposed
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Figure 3: Posterior probabilities of major birth defect as a function of βY for subjects with
missing major birth defect outcomes, ordered by possibly censored event time. The red line
is when βY is set at the estimated βY value, black lines from bottom to top correspond to
βY set from 0 to 5 with increment of 0.5. The last two subjects are censored.
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dashed lines denote point estimates.
group, which would have had a high chance of being spontaneously aborted had the women
not been exposed to the medication, to develop into live born infants.
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5.2. Principal effects
We now consider the principal effects as described in Section 4. Direct attempt to fit models
(20) - (22) failed because the ES algorithm could not converge with so few events and the
missing major birth defect outcomes. This is not surprising as more parameters need to be
estimated than in the ATE analysis above.
From Table 3 we see that very few observed data points are available to estimate the
parameters in the principal strata NN. Meanwhile most missing birth defect outcomes are
from the observed groups O(0, 1) and O(1, 1), which consist of the latent principal strata
(NS, NN) and NN, respectively. We have therefore decided to offset some of the parameters
among α0,NS, αD,NS, α0,NN and αD,NN as sensitivity parameters, and focus on the estimation
of the parameters in the SS strata, which appears to have most observed data points. We
carry out two sets of analysis below. We first offset the values of α0,NS, α0,NN and αD,NN
to be in the range of [−2, 0], [−2, 0] and [−2, 2], respectively, all with 0.5 increments. The
non-positive values of α0,NS and α0,NN are chosen to keep the overall birth defect rate under
10% in the entire sample. We also offset the values of αD,NS, α0,NN and αD,NN, and have
obtained similar results (see Supplemental Materials) as the first set described below.
Figure 5 shows the estimates αˆD,SS corresponding to different offset values of α0,NS,
α0,NN and αD,NN. From Figure 5 we see that the principal effect of the drug on major
birth defect among the always-survivors has an estimated OR over 3 for all values of the
three sensitivity parameters, and it remains significant at 0.05 level. This implies that if
a pregnant diseased woman will not experience SAB/stillbirth regardless of the exposure
status, exposure to the medication increases her risk of having major birth defects.
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Figure 5: Level plots of αˆD,SS. The corresponding p-values range from 0.023 to 0.046.
Figure 6 shows the estimated causal effect ̂log(ORM) of the drug exposure on SAB/Stillbirth,
as defined in (24). As one can see, the significance of this causal effect goes away as
Pˆ(G = NS) decreases and as Pˆ(G = NN) increases. These happen generally when α0,NN
becomes smaller, αD,NN becomes larger and α0,NS becomes larger.
28
−0.81 −0.81 −0.81 −0.8 −0.8 −0.79 −0.79 −0.78 −0.77
−0.86 −0.86 −0.85 −0.85 −0.84 −0.84 −0.83 −0.82 −0.81
−0.93 −0.92 −0.92 −0.92 −0.91 −0.9 −0.89 −0.89 −0.88
−1.01 −1.01 −1 −1 −0.99 −0.99 −0.98 −0.97 −0.97
−1.1 −1.1 −1.1 −1.09 −1.08 −1.08 −1.07 −1.07 −1.07
−0.48 −0.48 −0.47 −0.47 −0.47 −0.46 −0.45 −0.44 −0.43
−0.55 −0.55 −0.55 −0.54 −0.54 −0.53 −0.52 −0.51 −0.5
−0.67 −0.67 −0.66 −0.66 −0.65 −0.64 −0.63 −0.62 −0.61
−0.81 −0.81 −0.8 −0.8 −0.79 −0.78 −0.77 −0.77 −0.76
−0.96 −0.96 −0.95 −0.95 −0.94 −0.93 −0.93 −0.92 −0.92
−0.76 −0.76 −0.76 −0.75 −0.75 −0.74 −0.74 −0.73 −0.72
−0.81 −0.81 −0.81 −0.8 −0.8 −0.79 −0.78 −0.77 −0.77
−0.89 −0.89 −0.88 −0.88 −0.87 −0.86 −0.86 −0.85 −0.84
−0.98 −0.98 −0.97 −0.97 −0.96 −0.95 −0.95 −0.94 −0.94
−1.08 −1.08 −1.07 −1.07 −1.06 −1.06 −1.05 −1.05 −1.04
−0.2 −0.2 −0.2 −0.2 −0.19 −0.19 −0.18 −0.17 −0.16
−0.25 −0.25 −0.25 −0.24 −0.23 −0.22 −0.21 −0.2 −0.19
−0.39 −0.39 −0.38 −0.37 −0.36 −0.35 −0.34 −0.33 −0.33
−0.6 −0.59 −0.58 −0.58 −0.57 −0.56 −0.55 −0.54 −0.53
−0.81 −0.81 −0.8 −0.79 −0.78 −0.77 −0.77 −0.76 −0.76
−0.66 −0.66 −0.66 −0.65 −0.65 −0.64 −0.64 −0.63 −0.62
−0.72 −0.72 −0.72 −0.71 −0.71 −0.7 −0.69 −0.68 −0.67
−0.81 −0.81 −0.81 −0.8 −0.79 −0.79 −0.78 −0.77 −0.76
−0.92 −0.92 −0.92 −0.91 −0.9 −0.9 −0.89 −0.88 −0.88
−1.04 −1.04 −1.03 −1.03 −1.02 −1.01 −1.01 −1 −1
α0, NS = −0.5 α0, NS = 0
α0, NS = −2 α0, NS = −1.5 α0, NS = −1
−2 −1 0 1 2 −2 −1 0 1 2
−2 −1 0 1 2
−2.0
−1.5
−1.0
−0.5
0.0
−2.0
−1.5
−1.0
−0.5
0.0
αD, NN
α
0,
 N
N
−1.0
−0.8
−0.6
−0.4
−0.2
ATE on SAB
0.046 0.046 0.046 0.046 0.046 0.046 0.046 0.045 0.045
0.049 0.049 0.049 0.049 0.049 0.049 0.048 0.048 0.048
0.053 0.053 0.053 0.053 0.053 0.053 0.052 0.052 0.052
0.059 0.059 0.058 0.058 0.058 0.058 0.058 0.057 0.057
0.064 0.064 0.064 0.064 0.064 0.063 0.063 0.063 0.063
0.027 0.027 0.027 0.026 0.026 0.026 0.026 0.025 0.024
0.031 0.031 0.031 0.031 0.03 0.03 0.03 0.029 0.029
0.038 0.038 0.038 0.038 0.037 0.037 0.036 0.036 0.036
0.047 0.047 0.047 0.046 0.046 0.046 0.045 0.045 0.045
0.056 0.056 0.056 0.055 0.055 0.055 0.055 0.055 0.054
0.043 0.043 0.043 0.043 0.043 0.043 0.042 0.042 0.042
0.047 0.046 0.046 0.046 0.046 0.046 0.045 0.045 0.045
0.051 0.051 0.051 0.051 0.051 0.05 0.05 0.05 0.049
0.057 0.057 0.057 0.056 0.056 0.056 0.056 0.056 0.055
0.063 0.063 0.063 0.063 0.062 0.062 0.062 0.062 0.062
0.011 0.011 0.011 0.011 0.01 0.01 0.01 0.009 0.009
0.014 0.014 0.013 0.013 0.013 0.012 0.012 0.011 0.011
0.022 0.022 0.021 0.021 0.02 0.02 0.019 0.019 0.018
0.034 0.034 0.033 0.033 0.033 0.032 0.032 0.031 0.031
0.047 0.047 0.046 0.046 0.046 0.045 0.045 0.045 0.045
0.038 0.037 0.037 0.037 0.037 0.037 0.036 0.036 0.036
0.041 0.041 0.041 0.041 0.041 0.04 0.04 0.04 0.039
0.047 0.047 0.046 0.046 0.046 0.046 0.045 0.045 0.045
0.053 0.053 0.053 0.053 0.053 0.052 0.052 0.052 0.052
0.061 0.06 0.06 0.06 0.06 0.06 0.06 0.059 0.059
α0, NS = −0.5 α0, NS = 0
α0, NS = −2 α0, NS = −1.5 α0, NS = −1
−2 −1 0 1 2 −2 −1 0 1 2
−2 −1 0 1 2
−2.0
−1.5
−1.0
−0.5
0.0
−2.0
−1.5
−1.0
−0.5
0.0
αD, NN
α
0,
 N
N
0.01
0.02
0.03
0.04
0.05
0.06
P(G = NS)
0.041 0.041 0.041 0.041 0.041 0.041 0.042 0.042 0.042
0.04 0.04 0.04 0.04 0.04 0.041 0.041 0.041 0.042
0.039 0.039 0.039 0.039 0.039 0.04 0.04 0.04 0.04
0.037 0.037 0.037 0.038 0.038 0.038 0.038 0.039 0.039
0.035 0.035 0.036 0.036 0.036 0.036 0.037 0.037 0.037
0.047 0.047 0.047 0.047 0.048 0.048 0.048 0.049 0.049
0.046 0.046 0.046 0.046 0.046 0.047 0.047 0.048 0.048
0.044 0.044 0.044 0.044 0.044 0.045 0.045 0.046 0.046
0.041 0.041 0.041 0.042 0.042 0.042 0.043 0.043 0.043
0.038 0.038 0.039 0.039 0.039 0.039 0.04 0.04 0.04
0.042 0.042 0.042 0.042 0.042 0.042 0.043 0.043 0.043
0.041 0.041 0.041 0.041 0.041 0.042 0.042 0.042 0.043
0.039 0.039 0.04 0.04 0.04 0.04 0.041 0.041 0.041
0.038 0.038 0.038 0.038 0.038 0.039 0.039 0.039 0.039
0.036 0.036 0.036 0.036 0.037 0.037 0.037 0.037 0.037
0.052 0.052 0.052 0.052 0.052 0.053 0.053 0.053 0.054
0.051 0.051 0.051 0.052 0.052 0.052 0.053 0.053 0.054
0.049 0.049 0.049 0.05 0.05 0.05 0.051 0.051 0.051
0.045 0.045 0.046 0.046 0.046 0.047 0.047 0.047 0.048
0.041 0.041 0.042 0.042 0.042 0.043 0.043 0.043 0.043
0.044 0.044 0.044 0.044 0.044 0.044 0.045 0.045 0.045
0.043 0.043 0.043 0.043 0.043 0.043 0.044 0.044 0.044
0.041 0.041 0.041 0.041 0.042 0.042 0.042 0.043 0.043
0.039 0.039 0.039 0.039 0.04 0.04 0.04 0.04 0.041
0.037 0.037 0.037 0.037 0.037 0.038 0.038 0.038 0.038
α0, NS = −0.5 α0, NS = 0
α0, NS = −2 α0, NS = −1.5 α0, NS = −1
−2 −1 0 1 2 −2 −1 0 1 2
−2 −1 0 1 2
−2.0
−1.5
−1.0
−0.5
0.0
−2.0
−1.5
−1.0
−0.5
0.0
αD, NN
α
0,
 N
N
0.040
0.045
0.050
P(G = NN)
Figure 6: Level plots of the estimated causal effect of drug exposure on SAB/Stillbirth
̂log(ORM) (top) and the corresponding Pˆ(G = NS) (middle) and Pˆ(G = NN) (bottom).
The cells with red borders are significant at 0.05 level.
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In Table 3, O(0, 1) and O(1, 0) are the two larger observed groups with mixtures of two
principal strata each. In Figure 7 we show the distribution of the estimated (posterior)
principal strata membership Pˆ(Gi = NS|O) for those subjects in these two groups. We show
them under two extreme cases (α0,NS, α0,NN, αD,NN) = (−2,−2,−2) and (0, 0, 2), and one
intermediate case (α0,NS, α0,NN, αD,NN) = (−1,−1, 0). When writing out the expressions
(not shown) it is easy to see that Pˆ(Gi = NS|O) from the O(1, 0) group can only take
on two possible values, while those from the O(0, 1) group can take on many more. As
seen from the figure, the distribution of Pˆ(Gi = NS|O) remains relatively unchanged with
respect to the sensitivity parameters. It appears that the O(0, 1) group is almost equally
divided into the NS and NN strata, while only a small portion (about 5%) of the O(1, 0)
group belong to the NS stratum. The remaining 6 subjects in O(0, ?) and O(1, ?) are
presented in the Supplemental Materials.
Finally analogous to Figure 3, we also show the posterior probabilities of birth defect
Pˆ(Y = 1|O) in Figure 8 for those who are missing this outcome. A total of 5× 5× 9 = 225
lines are plotted corresponding to the different combinations of α0,NS, α0,NN and αD,NN
values. Pˆ(Y = 1|O) increases for each subject as each of the α0,NS, α0,NN and αD,NN
values increases, as expected. We see that subjects from the exposed group have higher
probabilities of birth defects than those from the unexposed group. At the highest extreme,
the average of the posterior probabilities of birth defects from the unexposed group is about
10% in these sensitivity analyses.
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Figure 7: Distribution of Pˆ(Gi = NS|O) when (α0,NS, α0,NN, αD,NN) =: (a) (-2, -2, -2), (b)
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Figure 8: The estimated Pˆ(Y = 1|O) for the 27 subjects with missing birth defect outcomes.
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6. Discussion
In this paper we have considered prospective pregnancy cohort studies where spontaneous
abortion often results in unknown major birth defect outcomes. By convention of coding
in the database a pregnancy is recorded as no birth defects unless one is found. Meanwhile
it is well established that a malformed fetus has an increased chance of being aborted
(Warkany, 1978). By modeling the data mechanism using the terathanasia theory, we are
able to turn the MNAR problem of major birth defects into an MAR setting by including
information on the spontaneous abortion outcome. Our approach using (5) is a selection
models approach for handling informative missing (Little and Rubin, 2019).
A second part of our work aims to properly handle the post-exposure variable live birth
versus spontaneous abortion or stillbirth. We found the principal strata to be a useful
framework for this. Due to the limited sample size and number of events, we are only able
to estimate the principal effect in the largest stratum, i.e. always survivors. The approach,
as well as R program, can be applied to larger data sets, where we should be able to estimate
all principal effects, as opposed to offsetting some of them as sensitivity parameters. For
other exposures that might not be protective against spontaneous abortion, one may wish
to do away with the monotonicity assumption, and consider four instead of three principal
strata.
As mentioned earlier while our data structure has some similarity with truncation by
death in the principal strata setting, the latter typically concerns longitudinal outcomes
over time. A common example is quality of life (QOL, or cognition function, etc.) that
is truncated by death. In these settings the QOL outcome does not exist once a person
dies, hence the only stratum of interest is always-survivors (and the principal effect is
called survivor average causal effect or SACE). Birth defects, on the other hand, already
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exist before the end of the pregnancy, be it live birth or SAB/stillbirth. And as we have
explained above, we are interested in the principal effects in all strata.
In our analysis the major birth defect Y is the outcome of interest. From Figure 1,
however, Y may also be seen as a mediator for the spontaneous abortion outcome (M,T ).
The decomposition of the total effect of exposure D on SAB into a direct effect and an
indirect effect through Y might be of interest, in understanding whether D directly causes
SAB or through major birth defects (and terathanasia). In this case the natural direct and
the natural indirect effects might be suitable as they describe the underlying mechanism
by which the exposure operates (Pearl, 2001).
Finally, to estimate the average treatment effect (and similarly the principal effects),
the structural logistic regression model (4) for the causal odds ratio is saturated. However,
we do impose a proportional hazards model in (5), as well as a propensity score model
to generate inverse probability weights. Since the models might be wrong, it would be of
interest to develop doubly robust or other robust approaches. This is an area for future
work.
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